Perseus Proteomics Inc. [4882.T]
TOKYO, Apr 01 (Pulse News Wire) – Perseus Proteomics Inc. (4882.T) received notification of a grant decision for its aggressive NK cell leukemia treatment drug, PPMX-T003, under the Medical Research and Development Promotion Project Fund Assistance Program managed by the National Institute of Biomedical Innovation, Health, and Nutrition for fiscal year 2026.
The grant, worth April 01, 2026, will support clinical trials led by physicians aimed at developing effective treatments for this rare and difficult-to-treat disease. Aggressive NK cell leukemia primarily affects adolescents and young adults, with median survival rates of less than two months due to rapid progression. Currently, there are limited treatment options available, making the development of new drugs highly sought after. PPMX-T003 targets transferrin receptor 1 (TfR1), which plays a crucial role in iron uptake within cells.
By inhibiting iron intake in cancer cells, PPMX-T003 aims to suppress their proliferation effectively. The funding program provides up to three fiscal years of support, with individual grants determined annually. Perseus Proteomics expects to receive the grant in March 2027, which will be recorded as long-term receivables. The impact on the company's performance for the fiscal year ending March 2027 is expected to be minor.
🟡 Confidence: Standard AI-translated content.